Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Kompel

Diagnostic Radiology Boston, MA Medical Doctor

NPI 1710184429 CMS profile 1152334

88 E Newton St, Boston, MA 02118

Open in the dashboard

General payments

$1,335,951

70 records reported · program years 2019–2025

Research payments

$16,300

Paid to them · 15 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$695,111 paid to institutions, not to them · program year 2023

Through program year 2025, Andrew Kompel of Boston, MA is reported in the CMS Open Payments database as having received $1,335,951 across 70 general payments and $16,300 in research payments paid to them. Separately, studies naming them as principal investigator received $695,111 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,381 22
2025 Research $5,180 7
2024 General $14,100 2
2023 General $4,700 4
2023 Research $4,600 2
2022 General $4,925 2
2021 General $677,325 8
2021 Research $4,920 3
2020 Research $1,600 3
2019 General $613,520 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Kompel
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Andrew Kompel were reported at $21,381. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Andrew Kompel Diagnostic Radiology median Middle half National median
2019 $613,520 $108 $29–$318 $163
2020 $0 $65 $21–$252 $114
2021 $677,325 $92 $24–$292 $132
2022 $4,925 $104 $29–$294 $149
2023 $4,700 $110 $29–$337 $160
2024 $14,100 $113 $30–$356 $164
2025 $21,381 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $1,314,570 48 payments
  2. Pacira Pharmaceuticals Incorporated $21,381 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,330,770 51 payments
  2. Travel and Lodging $4,233 12 payments
  3. Food and Beverage $948 7 payments
Products named General payments · program years 2019–2025
  1. IBRANCE $18,050 4 payments
  2. Zilretta $12,165 14 payments
  3. Exparel $9,216 8 payments
  4. CIBINQO $5,675 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $6,520 6 payments
  2. Hexal AG $5,180 7 payments
  3. Neurocrine Biosciences, Inc. $4,600 2 payments

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$18,383

Medicare's payments for the services billed

Medicare patients

1,099

Average age 70

Services billed

1,597

673 women, 426 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 54%
Diabetes 37%
Depression 33%
Chronic kidney disease 24%
Ischemic heart disease 20%
Heart failure 17%
Osteoporosis 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IBRANCE
  • PFIZER INC. $14,100
$14,100 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record